Reprint This Article

Investors are keeping a close eye on the drug firm’s vaccine advances. But the company’s longer-term fortunes may lie elsewhere.
Efraim Benmelech
If you are interested in reprinting this article, please contact us for permission, guidelines, code, and a canonical link. There is no fee for reprinting an article.
© Kellogg School of Management, Northwestern
University. All Rights Reserved. Privacy Policy.
University. All Rights Reserved. Privacy Policy.